Remission	remission	O	O
induction	induction	O	O
of	of	O	O
meningeal	meningeal	O	O
leukemia	leukemia	O	O
with	with	O	O
high-dose	high-dose	O	O
intravenous	intravenous	O	O
methotrexate	methotrexate	S_chemical	O
.	.	O	O

Twenty	twenty	O	O
children	children	O	O
with	with	O	O
acute	acute	O	B_disease
lymphoblastic	lymphoblastic	O	I_disease
leukemia	leukemia	O	I_disease
who	who	O	O
developed	developed	O	O
meningeal	meningeal	O	O
disease	disease	O	O
were	were	O	O
treated	treated	O	O
with	with	O	O
a	a	O	O
high-dose	high-dose	O	O
intravenous	intravenous	O	O
methotrexate	methotrexate	S_chemical	O
regimen	regimen	O	O
that	that	O	O
was	was	O	O
designed	designed	O	O
to	to	O	O
achieve	achieve	O	O
and	and	O	O
maintain	maintain	O	O
CSF	csf	B_chemical	O
methotrexate	methotrexate	S_chemical	O
concentrations	concentrations	O	O
of	of	O	O
10(-5	10(-5	O	O
)	)	O	O
mol/L	mol/l	O	O
without	without	O	O
the	the	O	O
need	need	O	O
for	for	O	O
concomitant	concomitant	O	O
intrathecal	intrathecal	O	O
dosing	dosing	O	O
.	.	O	O

The	the	O	O
methotrexate	methotrexate	S_chemical	O
was	was	O	O
administered	administered	O	O
as	as	O	O
a	a	O	O
loading	loading	O	O
dose	dose	O	O
of	of	O	O
6,000	6,000	O	O
mg/m2	mg/m2	O	O
for	for	O	O
a	a	O	O
period	period	O	O
of	of	O	O
one	one	O	O
hour	hour	O	O
followed	followed	O	O
by	by	O	O
an	an	O	O
infusion	infusion	O	O
of	of	O	O
1,200	1,200	O	O
mg/m2/h	mg/m2/h	O	O
for	for	O	O
23	23	O	O
hours	hours	O	O
.	.	O	O

Leucovorin	leucovorin	S_chemical	O
rescue	rescue	O	O
was	was	O	O
initiated	initiated	O	O
12	12	O	O
hours	hours	O	O
after	after	O	O
the	the	O	O
end	end	O	O
of	of	O	O
the	the	O	O
infusion	infusion	O	O
with	with	O	O
a	a	O	O
loading	loading	O	O
dose	dose	O	O
of	of	O	O
200	200	O	O
mg/m2	mg/m2	O	O
followed	followed	O	O
by	by	O	O
12	12	O	O
mg/m2	mg/m2	O	O
every	every	O	O
three	three	O	O
hours	hours	O	O
for	for	O	O
six	six	O	O
doses	doses	O	O
and	and	O	O
then	then	O	O
every	every	O	O
six	six	O	O
hours	hours	O	O
until	until	O	O
the	the	O	O
plasma	plasma	O	O
methotrexate	methotrexate	S_chemical	O
level	level	O	O
decreased	decreased	O	O
to	to	O	O
less	less	O	O
than	than	O	O
1	1	O	O
X	x	O	O
10(-7	10(-7	O	O
)	)	O	O
mol/L.	mol/l.	O	O
The	the	O	O
mean	mean	O	O
steady-state	steady-state	O	O
plasma	plasma	O	O
and	and	O	O
CSF	csf	B_chemical	O
methotrexate	methotrexate	S_chemical	O
concentrations	concentrations	O	O
achieved	achieved	O	O
were	were	O	O
1.1	1.1	O	O
X	x	O	O
10(-3	10(-3	O	O
)	)	O	O
mol/L	mol/l	O	O
and	and	O	O
3.6	3.6	O	O
X	x	O	O
10(-5	10(-5	O	O
)	)	O	O
mol/L	mol/l	O	O
,	,	O	O
respectively	respectively	O	O
.	.	O	O

All	all	O	O
20	20	O	O
patients	patients	O	O
responded	responded	O	O
to	to	O	O
this	this	O	O
regimen	regimen	O	O
,	,	O	O
16/20	16/20	O	O
(	(	O	O
80	80	O	O
%	%	O	O
)	)	O	O
achieved	achieved	O	O
a	a	O	O
complete	complete	O	O
remission	remission	O	O
,	,	O	O
and	and	O	O
20	20	O	O
%	%	O	O
obtained	obtained	O	O
a	a	O	O
partial	partial	O	O
remission	remission	O	O
.	.	O	O

The	the	O	O
most	most	O	O
common	common	O	O
toxicities	toxicities	O	S_disease
encountered	encountered	O	O
were	were	O	O
transient	transient	O	O
serum	serum	O	O
transaminase	transaminase	O	O
and	and	O	O
bilirubin	bilirubin	S_chemical	O
elevations	elevations	O	O
,	,	O	O
neutropenia	neutropenia	O	S_disease
,	,	O	O
and	and	O	O
mucositis	mucositis	O	S_disease
.	.	O	O

One	one	O	O
patient	patient	O	O
had	had	O	O
focal	focal	O	O
seizures	seizures	O	S_disease
and	and	O	O
transient	transient	O	B_disease
hemiparesis	hemiparesis	O	S_disease
but	but	O	O
recovered	recovered	O	O
completely	completely	O	O
.	.	O	O

High-dose	high-dose	O	O
intravenous	intravenous	O	O
methotrexate	methotrexate	S_chemical	O
is	is	O	O
an	an	O	O
effective	effective	O	O
treatment	treatment	O	O
for	for	O	O
the	the	O	O
induction	induction	O	O
of	of	O	O
remission	remission	O	O
after	after	O	O
meningeal	meningeal	O	O
relapse	relapse	O	O
in	in	O	O
acute	acute	O	B_disease
lymphoblastic	lymphoblastic	O	I_disease
leukemia	leukemia	O	I_disease
.	.	O	O

